Celsion Corporation
CLSN, a leading oncology drug development company, today
announced that the independent Data Monitoring Committee (DMC) for
the Company's HEAT Study, a fully enrolled, multinational,
double-blind, placebo-controlled, pivotal Phase III trial of
ThermoDox(R) in combination with radiofrequency ablation (RFA) for
hepatocellular carcinoma (HCC or primary liver cancer), has completed
a regularly scheduled review of all 701 patients enrolled in the
trial and has unanimously recommended that the HEAT Study continue
according to protocol to its final data readout. The HEAT Study is
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in